TIM-3 is frequently co-expressed with PD-1 (Curigliano et al. 2021), and its upregulation in NSCLC is considered a mechanism of adaptive resistance to PD-1 blockade (Andrews et al. 2019). Here, HAVCR2 is linked to non-small cell lung carcinoma.